About AQXP

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing slated to enter Phase 3 clinical trials in 2016 for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC); a debilitating, chronic condition that is estimated to affect millions of sufferers. Aquinox has a broad intellectual property portfolio surrounding compounds that activate SHIP1
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AQXP is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 6.5 B 6.5E+09 3,237 3237 0.0% 1E-05 87 K 87098
ITOT iShares Core S&P Total U.S. Stock Market ETF 21.0 B 2.1005E+10 3,548 3548 0.0% 0 15 K 15461
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.0% 5.80686E-06 12 K 12343